XKRX
019175
Market cap270mUSD
Jul 10, Last price
12,150.00KRW
1D
1.25%
1Q
-23.10%
Jan 2017
200.37%
Name
Shinpoong Pharmaceutical Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shinpoong Pharmaceutical Co., Ltd., a South Korean firm, specializes in the production and distribution of a broad spectrum of pharmaceutical goods. Its product offerings span various therapeutic categories, including cephalosporin and penicillin antibiotics, as well as a range of finished drug formulations. The company further supplies active pharmaceutical ingredients (APIs) and specialized medications like Pyramax, an anti-malarial treatment. Additionally, Shinpoong develops drugs for conditions such as hypercholesterolemia, knee osteoarthritis, shoulder periarthritis, and for preventing surgical adhesion, alongside its over-the-counter (OTC) products. With a notable international footprint, Shinpoong Pharmaceutical exports its remedies to approximately 50 countries globally. This company, established in 1962, is headquartered in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||